

## DAFTAR PUSTAKA

- Abogamal AF, Mahmoud E, Abdulhakiem S, Abdellatif S & Abdalaziz AF, 2014. Insulin resistance in patients with psoriatic arthritis. *Al Azhar Assiut Medical Journal*, 12(3): 95-116.
- Ahmed M and Gaffen SL, 2012. IL17 in obesity and adipogenesis. *Cytokine growth factor Rev*, 21 (6): 449-453.
- Albar Z, 2014. Arthritis psoriatik. In: Setiadi S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. *Buku Ajar: Ilmu penyakit dalam jilid I edisi VI*. Jakarta: Internapublishing. pp. 3173-3175.
- Aletaha D, Alasti F & Smolen JS, 2017. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. *Annals of the Rheumatic Disease*, 76:418-421.
- Amin Z & Bahar A, 2014. Tuberkulosis paru. In: Setiadi S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. *Buku Ajar: Ilmu penyakit dalam jilid I edisi VI*. Jakarta: Internapublishing. pp. 863-872.
- Anderson K, Zimmerman L, Caplan L & Michaud K, 2011. Measures of rheumatoid arthritis disease activity. *Arthritis Care & Research*, 63(S11): S14-S36.
- Angelo S, Tramontano G, Gillo M, Leccese P & Olivieri I, 2017. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. *Open Access Rheumatology : Research and Reviews*, 9: 21-28.
- Arıcan O, Aral M, Sasmaz S & Ciragil P, 2005. Serum levels of TNF- $\alpha$ , IFN- $\gamma$ , IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity, 5: 273-279.
- Askari A, Naghizadeh MM, Homayounfar R, Shahi A, Afsarian HM, Paknahad A, Derek KD & Ataollahi MR, 2016. Increased serum levels of IL-17A and IL-23 are associated with decreased vitamin D3 and increased pain in osteoarthritis. *Plus One*, 6: 1-8.

- Baek HJ, Yoo CD, Shin KC, Lee YJ, Kang AW, Lee EB, Han CW, Kim HA, Youn JI & Song YW, 2000. Spondylitis is the most common pattern of psoriatic arthritis in Korea. *Rheumatology International*, 19: 89–94.
- Bandinelli F, Scazzariello F, Fonseca EP, Santiago MB, Marcassa C, Nacci F, Cerinic MM, 2016. Low dose modified-release prednisone in axial spondyloarthritis: 3 month efficacy and tolerability. *Drug Design, Development and Therapy*, 10: 3717-3724.
- Baratawidjaja KG & Rengganis I, 2012. *Imunologi dasar*, edisi ke-10. Jakarta. Fakultas Kedokteran Universitas Indonesia. pp 197-216.
- Barnas JL & Ritchlin CT, 2015. Etiology and pathogenesis of psoriatic arthritis. *Rheumatic Disease Clinics of North America*, 41: 643-663.
- Bassukas ID, Kosmidou M, Gaitanis G, Tsiouri G & Tsianos E, 2011. Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease. *Acta Dermato-Venereologica*, 91(4): 444-446.
- Bergboer, JG., Zeeuwen, PL & Schalkwijk J, 2012. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. *Journal of Investigative Dermatology*; 132: 2320-2321.
- Bettelli E, Korn T, Oukka M & Kuchroo VK, 2008. Induction and effector functions of TH17 cells. *Nature*, 453: 1051-1057.
- Bhole VM, Choi HK, Burns LC, Vera Kellet C, Lacaille DV & Gladman DD, 2012. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. *Rheumatology*, 51:552-556.
- Blauvelt A & Chiricozzi, 2018. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. *Clinical Reviews in Allergy & Immunology*, 55:379-390.
- Boutet MA, Nerviani A, Afflitto GG & Pitzalis C, 2018. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. *International Journal of Molecular Sciences*, 19(530): 1-27.
- Bordignon V, Bultrini S & Prignano G, 2011. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory

- diseases, including lung cancer. *Journal of Biological Regulators and Homeostatic Agents*, 25(2): 213-220.
- Brockbank JE, Stein M, Schentag CT, Gladman DD, 2005. Dactylitis in psoriatic arthritis: a marker for disease severity?. *Annals of Rheumatic Diseases*, 64:188-190.
- Bruce IN, 2010. Clinical features of Psoriatic Arthritis In: Hochberg, Silman A, Smolen JS, Weinblatt M, Weisman M editors. *Rheumatology sixth edition. Elsevier*.pp 1183-1189.
- Bulek K, Liu C, Swaidani S, Wang L, Page RC & Gulen MF, 2011. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. *Nature Immunology*, 12: 844-852.
- Budamakuntla L, Loganathan E, Gundappa P & Kini T, 2017. IL-17 cytokine in psoriasis: before and after methotrexate and NBUBV phototherapy: A longitudinal study. *Clinical Dermatology Research Journal*, 2 (1):1-4.
- Camelia P, Loredana HP, Daniela D, Monica T, Maria S & Ana TL, 2016. Renal comorbidity in psoriatic arthritis patients. *ARS Medica Tomitana*, 1(22):43-49
- Chen C, Shao Y, Wu X, Huang C & Lu W, 2016. Elevated interleukin-17 levels in patients with newly diagnosed type 2 diabetes mellitus. *Biochemistry and Physiology*, 5:206
- Chimenti MS, Conigliaro P, Morello M, Zenobi R, Triggianese P, Perricone C, Novelli L, Bernardini S & Perricone R, 2015. A prospective study on inflammatory cytokines and bone metabolism mediators in patients affected by rheumatoid and psoriatic arthritis treated with adalimumab. *Journal Arthritis*, 4:3.
- Chimenti MS, Triggianese P, Conigliaro P, Tonelli M, Giqliucci G, Novelli L, Teoli M & Perricone R, 2017. 2 year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. *Clinical of Rheumatology*, 4: 1-8
- Chung CP, Avalos I, Oeser A, 2007. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease

- characteristics and cardiovascular risk factors. *Annals of the Rheumatic Diseases*, 66 (2): 208-214
- Ciprandi G, Fenoglio D, De Amici M, Quaglini S, Negrini S & Filaci G, 2008. Serum IL-17 levels in patients with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 122(3): 650-651.
- Cortvrindt C, Speeckaert R, Moerman A, Delanghe JR & Speeckaert MM, 2017. The role of interleukin-17A in the pathogenesis of kidney disease. *Journal of pathology*.pp 1-12.
- Colbert R, Monica L, Gerlinde L & Dawn P, 2009. HLA-B27 misfolding and spondyloarthropathies. *Prion*, 3 (1): 15-26.
- Costello P, 1999. Predominance of CD8+ T lymphocytes in psoriatic arthritis. *J Rheumatol*. 26(5):1117-24.
- Dikbass O, Tosun M, Bes C, Tonuk SB, Yilmaz O, Aksehirli & Soy M, 2016. Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. *International Journal of Rheumatic Diseases*, 19: 672-677.
- Dreiherr J, Freud T & Cohen AD, 2013. Psoriatic Arthritis and Diabetes: A Population-Based Cross-Sectional Study. *Dermatology Research and Practice*, 2013: 1-7
- Dreiherr J, Weitzman D, Shapiro J, Davidovici B & Cohen AD, 2008. Psoriasis and chronic obstructive pulmonary disease: a case-control study. *British Journal of Dermatology*, 159: 956-960.
- Dahlan S, 2017. Hipotesis korelatif. Statistik untuk kedokteran dan kesehatan. Cetakan keenam. Jakarta, Salemba Medika. pp 221-242.
- Dahlan S, 2017. Besar sampel aksis korelatif. Besar sampel dalam penelitian kedokteran dan kesehatan. Cetakan keenam. Jakarta, Salemba Medika. pp 69-103.
- DEPKES RI, 2014. Pedoman Nasional Penanggulangan Tuberkulosis. Departemen Kesehatan Republik Indonesia. Jakarta. pp 1-150.
- Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y & Qin LY, 2013. Expression of interleukin-17 associated with disease progression and liver fibrosis with

- hepatitis B virus infection: IL-17 in HBV infection. *BioMed Central. Diagnostic pathology*, 8:40.
- Eder L, Chandran V & Gladman DD, 2015. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. *Current Opinion Rheumatology*, 27: 91-98.
- Eder L, Chandran V, Cook R & Gladman DD, 2017. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. *The Journal of Rheumatology*.
- Eder L, Chandran V & Gladman DD, 2012. Gender-related differences in patients with psoriatic arthritis. *International Journal of Clinical Rheumatology*, 7(6): 641–649.
- Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A, Pereira D, Chandran V, Rosen CF & Gladman DD, 2013. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. *Annals Rheumatic Disease*, 72(5):715-720.
- Elabscience, 2018. Human IL-17 (Interleukin 17) ELISA Kit. Elabscience Biotechnology Inc.pp 1-11.
- Ehrenfeld M, 2012. Spondyloarthropathies. *Best practice & Research clinical Rheumatology*, 26: 135-145.
- Englbrecht M, Wang Y, Ronneberger M, Manger B, Vastesaegeer N, veale DJ & Schett G, 2010. Measuring Joint Involvement in Polyarticular Psoriatic Arthritis: An Introduction of Alternatives. *Arthritis Care & Research*, 62(7): 977-983
- Emmanuel D, Jain A, Mehra S, Usdadiya J, Jain V, CB M, Mary C & Negi V, 2016. Psoriatic arthritis: A comparative study between HLA\*B27 Positive and HLA\*B27 Negative Disease.
- Feizi A, Kazemnejad A, Hosseini M, Parsa-yekta Z & Jamali J, 2011. Assessing awareness level about warning sign cancer and its determinants in an Iranian General Population. *Journal of Health Population and Nutrition*, 29 (6): 656-659.
- Feldtkeller E & Erendsson J, 2008. Definition of disease duration in ankylosing spondylitis. *Rheumatology International*, 28: 693-696.

- FitzGerald O & Winchester R, 2009. Psoriatic arthritis: From pathogenesis to therapy. *Arthritis Research & Therapy*, 11: 214.
- Fitzgerald O & Elmamoun M, 2017. Psoriatic arthritis. In: Firestein GS, Budd RC, Harris ED, McInus IB, Ruddy S, Sergeant JS, editors. *Kelley & Firestein's Textbook of Rheumatology*, 11th ed. Philadelphia, pp. 1285-1308.
- Frers RAK, Bisoesndial RJ, Montoya SF, Kerzker E, Castilla R, Tak PP, Milei J & Capani F, 2015. Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. *IJC Metabolic & Endocrine*, 6:43-54.
- Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B & Uwagawa T, 2004. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. *Molecular Cell Biology*, 24: 7806-7819.
- Gaffen SL, 2009. Structure and signaling in the IL-17 receptor superfamily. *Natural Review Immunology*, 9(8):556.
- Gaffen SL, 2011. Recent advances in the IL-17 cytokine family. *Current Opinion in Immunology*, 23: 613-619.
- Gelfand JM, 2012. Metabolic syndrome in patients with psoriatic disease. *Journal Rheumatology Supplement*, 89: 24-28.
- Gani RA, 2014. Hepatitis C. In: Setiadi S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. *Buku Ajar: Ilmu penyakit dalam jilid I edisi VI*. Jakarta: Internapublishing. pp. 1972-1983.
- Gladman DD, Farewell VT, Wong K, Husted J, 1998. Mortality studies in psoriatic arthritis: results from a single outpatient center. Prognostic indicators for death. *Arthritis & Rheumatism*, 41: 1103-1110.
- Glatt S, Baeten D, Baker T, Griffiths M, Lonescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling M, Yeremenko N, Miossec P & Shaw S, 2018. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. *Annals of Rheumatic disease*, 77:523-532.

- Gottlieb B, Dann F & Menter A, 2008. "Psoriasis and the metabolic syndrome," *Journal of Drugs in Dermatology*, 7(6): 563-572.
- Gottlieb A & Narang K, 2013. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. *SAGE Journals*, 5 (5): 277-285.
- Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M & Koo JY, 2008. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. *Journal of the American Academy of Dermatology*, 58: 851-64.
- Gossec L, McGonagle D, Korotaeva T, Lubrano E, Miguel E, Ostergaard M & Behrens F, 2017. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. *The Journal of Rheumatology*, 45:1.
- Granata M, Skarmoutsou E, Trovato C, Rossi GA, Mazzarino MC, & D'Amico F, 2017. Obesity, Type 1 Diabetes, and Psoriasis: An Autoimmune Triple Flip. *Pathobiology*, 84:71–79.
- Griffiths CEM & Barker JNWN, 2010. Psoriasis. In: Burn T, Stephen B, Cox N. Rook's Textbook of Dermatology. 8<sup>th</sup> Edition. *Brithis: Wiley-Blackwell*. pp 201-2060.
- Gudjonsson, JE & Elder JT, 2012. Psoriasis. In : Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Eds. Fitzpatrick's Dermatology In General Medicine. 8<sup>th</sup>. New York: *Mc Graw Hill*. pp 197-231.
- Gudu T & Gossec L, 2018. Quality of life in psoriatic arthritis. *Expert Review of Clinical Immunology*, 1:1-54.
- Hassoon HJ, Risan FA & Muhaimen NA, 2014. Estimation the concentration of IL-23, and IL-17A in the sera of patients with psoriasis in Baghdad city Iraqi *Journal of Biotechnology*, 13(2): 75-85.
- Hawker GA, Mian S, Kendzerska T, French M, 2011. Measures of Adult Pain. *Arthritis Care & Research*, 63(S11): S240–S252.
- Helliwell PS & Kavanaugh A, 2014. Comparison of Composite Measures of Disease Activity in Psoriatic Arthritis Using Data From an Interventional Study With Golimumab. *Arthritis Care & Research*, 66(5): 749 -756

- Hermansyah, 2014. *Disease-modifying antirheumatic drugs (DMARD)*. In: Setiadi S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. *Buku Ajar: Ilmu penyakit dalam jilid I edisi VI*. Jakarta: Internapublishing. pp. 3319-3324.
- Husic R, Gretler J, Felber A, Graninger WB, Duftner C & Hermann J, 2014. Disparity between ultrasound and clinical findings in psoriatic arthritis. *Annals of the Rheumatic Disease*,73:1529-1536.
- Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E & Korendowych E, 2010. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. *Nature Genetic*, 42: 996-999.
- Husni ME, 2007. Classification and epidemiology of psoriatic arthritis. In: Hochberg, Silman A, Smolen JS, Weinblatt M, Weisman M editors. *Reumatology sixth edition*. Elsevier.pp 1179-1182.
- Jamshidi F, Bouzari N, Seirafi H, Farnaghi F & Firooz A, 2008. The Prevalence of Psoriatic Arthritis in Psoriatic Patients in Tehran, Iran. *Archives of Iranian Medicine*, 11( 2): 162 -165.
- Jindal S & Jindal N, 2018. Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship. *Cureus* 10(2): e2195.
- Jones SM, Armas J, Cohen M, Lovell CR, Evison G & Mchugh NJ, 1994. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. *British Journal of Rheumatology*; 33: 834-839.
- Jose V, Castell, Maria J, Gomez L, David M, Andus T, Geiger T, Trullenque R, Ricardo Fabra & Heinrich PC, 1989. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. *Federation of European Biochemical Societies*,242 (2): 237-239.
- KDIGO Clinical Practice Guideline for Acute Kidney Injury, 2018. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. *Kidney International Supplements*, 2(1): 1-138
- Khurshid MA, 2007. Current diagnosis dan treatment rheumatolog second edition. The McGraw-Hill Companies, 47(8). pp 1262
- Kalkan G & Karadag AS, 2014. Psoriatic Arthritis Epidemiology. *Eastern Journal of Medicine*, 19: 1-7.



- Khan AA, Alsahli MA & Rahmani AH, 2018. Myeloperoxidase as an Active Disease Biomarker:Recent Biochemical and Pathological Perspectives. *Medical sciences*, 6(33): 1-21.
- Kim TH, Uhm WS & Inman R, 2005. Pathogenesis of ankylosing spondylitis and reactive arthritis. *Current Opinion in Rheumatology*, 17:400-405.
- Kirkham BW, kavanaugh A & Reich K, 2013. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. *Immunology*, 141: 133-142.
- Kirkham B, Menon B, Taams LS, 2014. Immunological and Clinical Relationships of Synovial IL-17+ T Cells in Psoriatic Arthritis. *Arthritis Rheumatology*, 66: 1272-1281.
- Kolls JK & Linden A, 2004. Interleukin-17 Family Members and Inflammation. *Immunity*, 21:467-476.
- Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN & Mule PM, 2011. Psoriasis: A comprehensive review. *International Journal of Pharmacy and Life Sciences*, 2(6):857-877.
- Lai TL, Yim CW, Leung MC, Wong PY & Ng WL, 2018. Clinical characteristics and comorbidities of psoriatic arthritis (PsA) in Hong Kong. *Hong Kong Bulletin on Rheumatic Diseases*, 2: 47-55.
- Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P, Nadai P, Geerts A, Quertinmont E, Vercruyssen V, Le Moine O & De Weert D, 2009. The Interleukin-17 Pathway Is Involved in Human Alcoholic Liver Disease. *Hepatology*, 49(2): 646-657.
- Li JK, Nie L, Zhao YP, Qiang Zhang YQ, Wang X, Shuai S, Liu Y, Zhao H & Cheng L, 2016. IL-17 mediates inflammatory reactions via p38/c-Fos and JNK/c-Jun activation in an AP-1-dependent manner in human nucleus pulposus cells. *Journal of Translational Medicine*, 14 (77): 1-10.
- Li Y, Jiang L, Zhang S, Yin L, Ma L, He D & Shen L, 2012. Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. *Rheumatology International*, 32(8): 2415-2422.

- Love TJ, Zhu Y, Zhang Y, Burns LW, Ogdie A, Gelfand Jm & Choi HK, 2012. Obesity and the risk of psoriatic arthritis: a population-based study. *Annals of rheumatic diseases*, 71:1273-1277.
- Louie GH & Bringham C, 2013. *Psoriatic arthritis*, 3rd edition. In: imboden JB, Hellman DB, Stone JH. *Current diagnosis & treatment*. pp 171-176.
- Lockshin B, Balagula Y & Merola JF, 2018. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. *Journal of the American Academy of Dermatology*, 79(2): 345-352.
- Lubberts E, 2015. The IL-23-IL-17 axis in inflammatory arthritis. *Nature Reviews Rheumatology*, 11: 415-429.
- Lubrano E & Perrotta FM, 2016. Secukinumab for ankylosing spondylitis and psoriatic arthritis. *Therapeutics and Clinical Risk Management*, 12: 1587-1592.
- Mahmood F & Helliwell P, 2016. Psoriatic arthritis: a review. *European Medical Journal Rheumatology*, 3(1): 114-117.
- McGuckin M, Eri R, Das I, Lourie R & Florin T, 2010. ER stress and the unfolded protein response in intestinal inflammation. *The American Journal of Physiology-Gastrointestinal and liver physiology*, 298: G820-G832.
- McHugh K & Bowness P, 2012. The link between HLA-B27 and SpA-new ideas on an old problem. *Rheumatology*, 51:1529-1539.
- Mease PJ, 2011. Measures of Psoriatic Arthritis. *Arthritis Care & Research*, 63 (S11): S64-S85.
- Mease P, 2015. IL-17 inhibition in spondyloarthritis: a targeted approach in psoriatic arthritis. *European Medical Journal*, 2 (1): 55-64.
- Mease PJ & Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, Northington R, Fulman J, Bananis E, Boggs R, Alvarez D, 2013. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/ North American dermatology clinics. *Journal American Academy of Dermatology*, 69: 729-735.
- Mease P, Heijde DVD, Landewe R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L & Abrams K, 2018. Secukinumab improves active psoriatic arthritis symptoms and inhibits

- radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Annals of Rheumatic diseases*, 77: 890-897.
- Melis L, Vandooren B, Kruithof E, Jacques P, Vos MD, Mielants H, Verbruggen G, Keyser FD & Elewauti D, 2014. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. *Annals of the Rheumatic Disease*, 69: 618–623.
- Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL & Gordon KB, 2008. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *Journal of the American Academy of Dermatology*, 58: 826-850.
- Menon B, Gullick NJ & Walter GJ, Rajasekhar M, Garrood T, Evans HG, 2014. Interleukin-17+CD8+T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression. *Arthritis & Rheumatology*, 66: 1272-1281.
- Miossec P & Kolls JK, 2012. Targeting IL-17 and Th17 cells in chronic inflammation. *Nature Reviews Drug Discovery*, 11(10): 763-776.
- Miossec P, Korn T & Kuchroo VK, 2009. Interleukin-17 and type 17 helper T cells. *New England Journal of Medicine*, 361: 888–898.
- Moneim AB, Bakery HH & Allam G, 2018. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. *Biomedicine & Pharmacotherapy*, 101: 287-292.
- Moseley TA, Haudenschild DR, Rose L & Reddi AH, 2003. Interleukin-17 family and IL-17 receptors. *Cytokine & growth factor reviews*, 14: 155-174.
- Moghaddassi M, Shahram F, Chams-Davatchi C, Najafizadeh SR & Davatchi F, 2009. Different aspects of psoriasis arthritis: Analysis of 150 Iranian Patients. *Archives Iranian Medicine*, 12 (3): 279-283.
- Mrabet D, Laadhar L, Sahli H, Zouari B, Haouet S, Makni S & Sellami S, 2013. Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. *Rheumatology International*, 33: 265-266.

- Nehring SM & Patel BC, 2019. C Reactive Protein (CRP). In: StatPearls. Treasure Island (FL).
- Nurdjanah S, 2014. Sirosis hati. In: Setiadi S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. *Buku Ajar: Ilmu penyakit dalam jilid I edisi VI*. Jakarta: Internapublishing. pp. 1978-1983.
- Ory PA, Gladman DD & Mease PJ, 2005. Psoriatic arthritis and imaging. *Annual Rheumatic Disease*, 64(2): 55-57.
- PERKI, 2015. Pedoman Tatalaksana Gagal Jantung (edisi pertama). Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI).pp 1-48.
- Petersen AMW & Pedersen BK, 2005. The anti-inflammatory effect of exercise. *Journal of Applied Physiology*, 98: 1154–1162.
- Pitzalis C, Kelly S, Humby F, 2013. New learnings on the pathophysiology of RA from synovial biopsies. *Current Opinion in Rheumatology*, 25:334-344.
- Polachek A, Touma Z, Anderson M & Eder L, 2017. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. *Arthritis Care & Research*, 69(1): 67-74.
- Parment S, 2004. Coronary Artery Disease. *The Journal of the American Medical Association*, 292(20): 2540
- Przepiera Bwdzak H, Fischer K & Brzosko M, 2015. Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. *Hindawi Publishing Corporation Mediators of Inflammation*, 7: 1-7.
- Puig L, 2018. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. *International journal of molecular sciences*, 19(58):1-19.
- Puksic S, King PB, Sexton J, Michelsen B, Kvien T & Hammer HB, 2018. DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs *Rheumatic musculoskeletal diseases (RMD) Open*; 4:e000765.
- Punzi L, Pianon M, Rossini P, Schiavon F & Gambari PF, 1999. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. *Annals of the Rheumatic diseases*, 58: 226-229.

- Queiro R, Morante I, Cabezas I, & Acasuso, 2016. HLA-B27 and psoriatic disease: a modern view of an old relationship. *Rheumatology*, 55: 221-229.
- Queiro R, Tejon P, Coto P, Alonso S, Alperi M, Sarasqueta C, Gonzalez S, Martinez Borra J, Lopez Larrea C & Ballina J, 2013. Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis. *Clinical and Developmental Immunology*, 13: 1-7.
- Raychaudhuri SP, Raychaudhuri SK & Genovese MC, 2012. IL-17 receptor and its functional significance in psoriatic arthritis. *Molecular Cellular Biochemistry*, 359: 419-429.
- Regana MS, Dilme AE, Pig L, Carrascos JM, Ferran A, Herranz P, Bustinduy M, Estebarez L, Alsina M, Rodriguez M, Lopez F, Moreno C, Romero B & Vidalm MD, 2010. Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group. *Actas Dermo-Sifiliograficas*, 101(2):156-163.
- Ritchlin CT, Colbert RA & Gladman DD, 2017. Psoriatic Arthritis. *The New England Journal of Medicine*, 376 (10): 957-970.
- Salaffi F, Ciapetti A, Carotti M, Gasparini S & Gutierrez M, 2014. Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World. *Hindawi Publishing Corporation BioMed Research International*. pp.1-12
- Sarkar S, Justa S, Brucks M, Endres J, Fox DA, Zhou X, Alnaimat F, Whitaker B, Wheeler JC & Jones BH, 2014. Interleukin (IL)-17A, F and AF in inflammation: A study in collagen-induced arthritis and rheumatoid arthritis: IL-17 subtypes in inflammatory arthritis. *Clinical & Experimental Immunology*, 177: 652–661.
- Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A & Oriente CB, 1984. Psoriatic arthritis in psoriatic patients. *British Journal of Rheumatology*, 23: 246-250.
- Schoels MM, Aletaha D, Alasti F & Smolen JS, 2016. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. *Annals of Rheumatic Diseases*, 75: 811-818.

- Shiber MD & Molad MDY, 2016. Elevated c-reactive protein level predicts earlier treatment with tumor necrosis factor-alpha inhibitors in Psoriatic Arthritis. *Israel medical association journal (IMAJ)*, 18: 279-282.
- Siew LQC, Wu SY, Ying S & Corrigan, 2017. Cigarette smoking increases bronchial mucosal IL-17A expression in asthmatics, which acts in concert with environmental aeroallergens to engender neutrophilic inflammation. *Clinical Experimental Allergy*, 47(6): 740-750.
- Sigmore A, 2013. About inflammation & infection. *EJNMMI Research Springer Open Journal*, 3 (8): 1-2.
- Sitepoe M, 2000. Kekhususan Rokok Indonesia. Jakarta:Grasindo,hal : 87
- Sheng Chen W, Sheng Chang Y, Chia Lin K, Chih Lai C, Hung wang S, Hung Hsiao K, Ting Lee H, Han Chen M, Youh Tsai C & Tei Chou C, 2012. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. *Journal of the Chinese Medical Association*, 75; 303-308.
- Sherma E, Syngle A & Khrisnan P, 2015. Endothelial progenitor cell biology in psoriatic arthritis patients in the absence of traditional cardiovascular risk. *Indian Journal of Rheumatology*, 11: 14-20.
- Smith JA & Colbert RA, 2014. Review: the interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. *Arthritis Rheumatology*, 66: 231-241.
- Smolen JS, Schoels M & Aletaha D, 2015. Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. *Clinical and experimental Rheumatology*, 33((93): S48-S50.
- Sokka T & Pincus T, 2005. Quantitative joint assessment in Rheumatoid arthritis. *Clinical and experimental Rheumatology*, 23(39): S58-S62.
- Sonder SU, Saret S, Tang W, Sturdevant DE, Porcella SF & Siebenlist U, 2011. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. *The Journal of biological chemistry*, 286: 12881-12890.

- Soemohardjo S & Gunawan S, 2014. Hepatitis B kronik. In: Setiadi S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. *Buku Ajar: Ilmu penyakit dalam jilid I edisi VI*. Jakarta: Internapublishing. pp. 1963-1971.
- Sundaru H & Sukamto, 2014. Asma bronkial. In: Setiadi S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. *Buku Ajar: Ilmu penyakit dalam jilid I edisi VI*. Jakarta: Internapublishing. pp. 478-488.
- Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos LE, 2014. The IL-23/IL-17 Axis in Psoriatic Arthritis. *Autoimmun Review*, 13(0): 496-502
- Tam LS, Gu J & Yu D, 2010. Pathogenesis of ankylosing spondylitis. *Nature Reviews. Rheumatology*, 6: 399-405.
- Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, Ryffel B & Sun B, 2013. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. *Journal immunology*, 191: 1835-1844.
- Tassioulas I, Duncan SR, Centola M, Theofilopoulos AN & Boumpas DT, 1999. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. *Human Immunology*, 60: 479-491
- Thomas J, 2016. Psoriasis as a systemic disease . In Kumar P, Balaji SR, Devaraj DK. *Textbook of Psoriasis*, 1st edition, New Delhi, India: Jaypee Brothers Medical Publishers, 8: 151-172.
- Toussiro E, Aubin F & Dumoulin, 2014. Relationships between adipose tissue and psoriasis, with or without arthritis. *Frontiers of immunology*, 368 (5): 1-8.
- Torrado E & Cooper AM, 2010. IL-17 and Th 17 cells in tuberculosis. *Cytokine Growth Factor Reviews*, 21(6): 455-462.
- Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J & Derry J, 2006. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. *Journal of immunology*, 177: 36-39.
- Valastyan J & Lindquist S, 2014. Mechanisms of protein-folding diseases at a glance. *Disease Models & Mechanisms*, 7: 9-14.
- Vijayakumaran N, Asokan N, Krishnan J & Narayanan B, 2016. Clinical and radiological findings in psoriatic arthritis: A hospital-based cross-sectional study. *Muller Journal of Medical Sciences and Research*, 7(2) : 91-95.

- Verma I, Syngle A & Krishan P, 2016. Endothelial progenitor cell biology in psoriatic arthritis patients in the absence of traditional cardiovascular risk. *Indian Journal of Rheumatology*, 11: 14-20.
- Wade SM, Canavan M, McGarry T, Low C, Wade SC, Mullan RH, Veale DJ & Fearon U, 2019. Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. *Annual Rheumatic Disease*, 78: 350-354
- Wang EA, Suzuki E, Maverakis E & Adamopoulos IE, 2017. Targeting IL-17 in psoriatic arthritis. *European Journal of Rheumatology*, 4: 272-277.
- Wang Z, Wang X, Chen Z, Zhang L & Zhu M, 2016. Distribution of High-Sensitivity C-Reactive Protein and Its Relationship with Other Cardiovascular Risk Factors in the Middle-Aged Chinese Population. *International Journal Environmental Research and Public Health*, 13; 872.
- Westerweel PE & Verhaar MC, 2009. Endothelial progenitor cell dysfunction in rheumatic disease. *Nature Reviews Rheumatology*, 5:332-340.
- Wong PCH, Leung YY, Li Ek & Tam LS, 2012. Measuring Disease Activity in Psoriatic Arthritis. *International journal of rheumatology*, 2012:1-10.
- Wu F, Xu J, Huang Q, Han J, Duan L, Fan J, Guo M, Hu G, Chen L, Zhang S, Tao X & Jin Y, 2016. The Role of Interleukin -17 in Lung Cancer. *Hindawi Publishing Corporation mediators of inflammation*. pp. 1-6.
- Yang B, Kang H, Fung A, Zhao H, Wang T & Ma D, 2014. The Role of Interleukin 17 in Tumour proliferation, Angiogenesis, and Metastasis. *Hindawi Publishing Corporation mediators of inflammation*. pp. 1-12.
- Yanzi JG, Schneeberger E, Cerda OL, Zaffarana C, Landi M, Roseff MG, Zamora N, Cazenave T, Kohan P, Buschiazzi E & Citera G, 2015. Construct validity of disease activity for Psoriatic Arthritis Composite Index and Tentative Cut-Off Values in a Cohort of Patients with Psoriatic Arthritis. *Arthritis Rheumatology*, 67 (10).
- Yasumi Y, Takikawa Y, Endo R & Suzuki K, 2007. Interleukin-17 as a new marker of severity of acute hepatic injury. *The Japan Society of Hepatology. Hepatology Research*, 37: 248–254.



- Zaffarana C, Gallino Yanzi J, Cerda OL, Landi M, Schneeberger E & Citera G, 2016. Prevalence of Obesity in Patients with Psoriatic Arthritis and Its Impact on the Severity of the Disease. *Arthritis Rheumatology*, 68(10): 27-68.
- Ziolkowska M, Koc A, Luszczkiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H & Maslinski, 2000. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. *Journal of Immunology*, 164(5): 2832-2838.
- Zuurbier KWM, Berg JDVD, Gelder BFV & Muijsers AO, 1992. Initial chlorinating activity at neutral pH, compound II, and III formation, and stability towards hypochlorous acid and high temperature. *European Journal of Biochemistry*, 205:737-742.